Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Laivuori, H.
Right arrow Articles by Ylikorkala, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Laivuori, H.
Right arrow Articles by Ylikorkala, O.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 16, No. 8, 1632-1635, August 2001
© 2001 European Society of Human Reproduction and Embryology

Comparison between 1 year oral and transdermal oestradiol and sequential norethisterone acetate on circulating concentrations of leptin in postmenopausal women

H. Laivuori1, H.A. Koistinen2,4, S.-L. Karonen3, B. Cacciatore1 and O. Ylikorkala1,5

1 Department of Obstetrics and Gynaecology, PO Box 140, 2 Department of Medicine, Division of Geriatrics, PO Box 340, and 3 Department of Clinical Chemistry, PO Box 360, Helsinki University Central Hospital, FIN-00029 HYKS, Finland

BACKGROUND: Oral and transdermal postmenopausal hormone replacement therapy (HRT) affects lipid and glucose metabolism differently, which is of significance in the release of leptin by adipocytes. Moreover, oestrogen and progesterone can stimulate leptin secretion in women of reproductive age. Therefore, we compared the effects of oral and transdermal oestrogen plus progestin regimen on plasma leptin in 38 healthy postmenopausal women with normal body mass index (BMI), who wished to use HRT to control incapacitating climacteric symptoms. METHODS: The women were randomized to treatment with oral HRT (2 mg oestradiol on days 1–12, 2 mg oestradiol plus 1 mg norethisterone acetate (NETA) on days 13–22, and 1 mg oestradiol on days 23–28, n = 19), or with transdermal HRT (50 µg/day of oestradiol on days 1–13, and 50 µg oestradiol plus 250 µg/day NETA on days 14–28, n = 19) for 1 year. Plasma samples were collected before and at oestradiol + NETA phase after 2, 6 and 12 months treatment and were assayed for leptin. RESULTS: The baseline leptin, ranging from 3.3 to 34.9 µg/l, was significantly associated with BMI (r = 0.78, P < 0.0001 ), but showed no difference between women in oral HRT (geometric mean 13.9 µg/l, 95% confidence interval (CI) 10.1–17.6 µg/l) or transdermal HRT group (geometric mean 12.0 µg/l, 95% CI 9.7–14.3 µg/l). Neither oral nor transdermal oestradiol + NETA caused any significant changes in plasma leptin (or BMI) after 2, 6, or 12 months of treatment. CONCLUSION: Leptin is an unsuitable factor to detect oestradiol + NETA-induced metabolic changes in postmenopausal women.

Key words: hormone replacement therapy/leptin/menopause

4 Present address: INSERM U449, Faculte de Medecine, R.T.H. Laennec, Rue Guillaume Paradin, F-69372 LYON Cedex 08, France

5 To whom correspondence should be addressed. E-mail: olavi.ylikorkala{at}hus.fi


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.